Drug Trial Radar · NCT05120830
NTLA-2002 in Adults With Hereditary Angioedema (HAE)
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
37
Actual
Start
Dec 10, 2021
Primary completion
Apr 4, 2024
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Intellia TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).
Conditions
- Hereditary Angioedema
Interventions
Biological NTLA-2002Biological
CRISPR/Cas9 gene editing system delivered by LNP for IV administration
Normal Saline IV AdministrationOther
The administration of IV normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of NTLA-2002 as determined by adverse events (AEs) and dose limiting toxicities (DLTs)Time frame: From NTLA-2002 infusion up to week 104 post-infusion
- Number of HAE attacks per month (Weeks 1-16)Time frame: From study drug infusion up to week 16 post-infusion
Locations
9 sites in 6 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Campbelltown, Australia
Clinical Trial Site
Grenoble, France
Clinical Trial Site
Lille, France
Clinical Trial Site
Paris, France
Clinical Trial Site
Berlin, Germany
Clinical Trial Site
Frankfurt, Germany
Clinical Trial Site
Amsterdam, Netherlands
Clinical Trial Site
Auckland, New Zealand
Clinical Trial Site
Cambridge, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.